- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 13:31 | BMS' Opdivo combo misses the mark in pancreatic cancer | ||
| 13:31 | UPDATED: J&J expands US partnership for coronavirus treatments | ||
| 12:31 | US backs Sanofi's 'fast-track' coronavirus vaccine | ||
| 12:31 | FDA sets June decision date for Tecentriq monotherapy in NSCLC | ||
| 11:31 | Pfizer's Vyndaqel is first EU therapy for ATTR cardiomyopathy | ||
| 11:31 | Measuring what matters: how to create the right KPIs for your brand, launch and portfolio | ||
| Di | Ex-Sandoz exec admits role in generic drug price-fixing plot | ||
| Di | Merck's Ebola vaccine wins approval in four African countries | ||
| Di | ReNeuron set for recovery after Woodford stake sale | ||
| Di | Servier and Oncodesign reach first milestone in Parkinson's partnership | ||
| Di | Bayer shares dip as Novartis gets EU okay for Beovu in wet AMD | ||
| Di | Weirdos and misfits | ||
| Mo | SMC enables access to Kyowa Kirin's Crysvita for rare bone disease | ||
| Mo | BMS unveils long-term results for Opdivo in kidney cancer | ||
| Mo | Roche's PD-L1 inhibitor Tecentriq approved in China for SCLC | ||
| Mo | After FDA refusal, Takeda builds case for subcutaneous Entyvio | ||
| Mo | US states reject drug distributors' opioid settlement | ||
| Mo | New strategic blueprint: the new first questions | ||
| Fr | Seattle Genetics wins FDA priority review for oral HER2 drug | ||
| Fr | AZ revenues rise, but it says coronavirus could hit 2020 | ||
| Fr | FDA begins speedy review of BMS' CAR-T liso-cel | ||
| Fr | Eisai agrees to pull obesity drug Belviq after safety alert | ||
| Fr | 20 for 2020 - Five pharma companies to watch | ||
| Do | imc group appoints Amber Fensome to senior leadership position | ||
| Do | M Booth Health appoints Karen Strauss to lead strategy and innovation |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
